Home>Topics>Stocks>Exelixis

Exelixis EXEL

  1. All
  2. Commentary
  3. Headlines
    1. Exelixis reports on November 4

      Headlines

      Tue, 14 Oct 2014

      Exelixis ( EXEL +4.1% ) will report Q3 results on November 4 after the close. The conference call will begin at 2:00 pm PT/5:00 pm ET. Consensus view is a loss of ($0.37) on revenues of $6.7M. Post your comment!

    2. Ad Comm smacks down Sonacare's HIFU device for prostate cancer

      Headlines

      Fri, 3 Oct 2014

      risks. Briefing docs Prostate cancer therapy-related tickers:( TKAI -2.1% )( MDVN +1.2% )( NYMX +4.8% )( EXEL -0.3% )( PGNX +2.8% )( MRK +1.8% )( ADXS +2.7% )( EBS +1.8% )( EDAP +3% )( ISIS +2.1% )( NVGN

    3. Update: Exelixis Announces Very Positive Results From The CoBRIM Trial - Impacts To My Bull Thesis

      Headlines

      Mon, 29 Sep 2014

      By Christopher F. Davis : Exelixis , Inc. (NASDAQ: EXEL ) just announced very positive results positive results from coBRIM, the Phase III pivotal trial conducted by EXEL 's collaborator Genentech, a member of the Roche (OTCQX

    4. Cobimetinib Combo Results are Positive, but Melanoma Landscape Is Becoming More Challenging

      Commentary

      Mon, 29 Sep 2014

      Exelixis and partner Roche reported positive detailed results for their Phase III study of MEK inhibitor cobimetinib in combination with

    5. Premarket Gainers / Losers

      Headlines

      Mon, 29 Sep 2014

      Gainers: AMBI +87% . ATHL +25% . AMAG +21% . TIBX +21% . DWA +20% . ALIM +16% . NVGN +15% . EXEL +15% . PSDV +8% . CYTR +6% . Losers: TNXP -49% . CVEO -38% . PBR -11% . [[PBR-A]] -11% . CNET -9% . BBD -8

    6. UPDATE 1-Roche, GSK melanoma pill combinations look similar in showdown

      Headlines

      Mon, 29 Sep 2014

      * Shares in Roche's biotech partner Exelixis jump 20 pct (Adds Exelixis share price jump, more on treatment debate)

    7. Exelixis up on clinical trial results

      Headlines

      Mon, 29 Sep 2014

      Shares of micro cap Exelixis (NASDAQ: EXEL ) are up 26% premaket on healthy ..... cobimetinib announced today by Roche. Exelixis discovered the drug internally ..... in late 2006. In November 2013, Exelixis exercised its option to co-promote

    8. Anika Therapeutics: A Recent Greenblatt Small Cap Biotech Pick

      Headlines

      Tue, 16 Sep 2014

      Investor : A Greenblatt Magic Formula screen for drug companies with market cap> $500M on 10/17/2012 identified Exelixis (NASDAQ: EXEL ), Momenta (NASDAQ: MNTA ), Pozen (NASDAQ: POZN ), and Questcor (NASDAQ: QCOR ). An equally weighted

    9. Exelixis' ( EXEL ) CEO Michael Morrissey Presents at Morgan Stanley Healthcare Conference (Transcript)

      Headlines

      Tue, 9 Sep 2014

      By SA Transcripts : Exelixis , Inc. (NASDAQ: EXEL ) Morgan Stanley Healthcare Conference ..... s my pleasure to introduce Exelixis , a biopharmaceutical company ..... Joining me here on stage from Exelixis is Dr. Michael Morrissey, the

    10. Exelixis Fails in Key Prostate Cancer Trial; Dramatically Lowering Fair Value Estimate

      Commentary

      Tue, 2 Sep 2014

      Exelixis announced Monday that its key Phase III COMET-1 trial in men with metastatic ..... statistically significant (p value of 0.21). Based on the trial result, Exelixis plans to halt its clinical program in prostate cancer and reduce its workforce

    « Prev12345Next »
    Content Partners